HEALWELL AI stock analysis
HEALWELL AI (HWAIF) Stock Price & Analysis
HWAIF Stock Chart & Stats
- Day’s Range
- $0.40 - $0.42
- 52-Week Range
- $0.39 - $0.89
- Previous Close
- $0.41
- Volume
- N/A
- Average Volume (3M)
- 40.17K
- Market Cap
- $141.42M
- Enterprise Value
- $297.32M
- Total Cash (Recent Filing)
- $32.61M
- Total Debt (Recent Filing)
- $86.32M
- Price to Earnings (P/E)
- ―
- Beta
- 1.13
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- -0.02
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Recurring Revenue Base
Recurring revenue provides greater visibility than episodic project work and can support more predictable planning, retention and cash generation. Its 70% share of quarterly revenue indicates HEALWELL is building a more durable software-oriented business model as healthcare customers adopt its platforms.
Scaling Growth And Operating Improvement
The combination of strong revenue expansion, sharply higher adjusted EBITDA and improved operating cash flow shows meaningful operating leverage as the business scales. If sustained, these gains can strengthen reinvestment capacity and improve the economics of HEALWELL’s expanding healthcare software platform.
Clinical AI Validation
A substantial peer-reviewed evidence base can differentiate HEALWELL from less-validated AI offerings and support adoption by healthcare organizations. Demonstrated improvements in treatment optimization strengthen the product’s clinical credibility, which may help sustain enterprise relationships and broader workflow deployment.
Bears Say
Persistent Bottom-Line Losses
Despite positive EBITDA, continued EBIT and net losses show that HEALWELL has not yet established durable bottom-line profitability. Ongoing overhead and other costs can limit internally funded growth, keep returns on equity negative, and make sustained earnings conversion dependent on further operating improvements.
Leverage And Liquidity Pressure
Operating near debt-facility thresholds reduces financial flexibility while the company is still scaling and reporting losses. The upcoming related-party loan maturity adds refinancing or repayment pressure, potentially diverting cash from product investment and increasing dependence on asset monetization or equity-based settlement.
Uneven Segment Momentum
Weakness in Life Sciences and declining Data Science and AI revenue indicate that growth is not yet broad-based across HEALWELL’s operations. The transition toward recurring healthcare-system contracts may ultimately improve quality, but near-term segment disruption can create uneven revenue progression and execution risk.
HWAIF FAQ
What was HEALWELL AI’s price range in the past 12 months?
What is HEALWELL AI’s market cap?
When is HEALWELL AI’s upcoming earnings report date?
How were HEALWELL AI’s earnings last quarter?
Is HEALWELL AI overvalued?
Does HEALWELL AI pay dividends?
What is HEALWELL AI’s EPS estimate?
How many shares outstanding does HEALWELL AI have?
What happened to HEALWELL AI’s price movement after its last earnings report?
Which hedge fund is a major shareholder of HEALWELL AI?
What is the TipRanks Smart Score and how is it calculated?
HEALWELL AI Stock Smart Score
Company Description
HEALWELL AI
Healwell AI Inc., a Toronto-based healthcare technology firm established in 2012, specializes in leveraging artificial intelligence and data science to advance preventative medical care. The company develops an AI-powered platform designed to assist healthcare providers with crucial decision-making. They maintain a significant strategic partnership with WELL Health Technologies Corp., focusing on accelerating the expansion and innovation of AI-driven healthcare solutions. Prior to its current name, adopted in October 2023, the organization was known as MCI Onehealth Technologies Inc.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- James Samuel Lee
- Employees
- 570
- Website
- www.healwell.ai
- Address
- 4881 Yonge Street, Toronto, ON, M6G 1A1, CA
HEALWELL AI (HWAIF) Earnings & Revenues
HWAIF Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, with strong revenue and adjusted EBITDA growth, improved operating cash flow, expanding recurring revenue, major enterprise agreements, a stronger HIE pipeline and continued clinical validation of the AI platform. These positives were tempered by weak Q3 Life Sciences performance, a lower quarterly gross margin, declining reported Data Science and AI revenue, milestone-dependent revenue recognition, cash and debt considerations, and early-stage go-to-market capacity. Management remained confident in the transition toward recurring global healthcare-system and SaaS revenue.
View all HWAIF earnings summariesHWAIF Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 4 | 15 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 0 | 0 | 12 |












